Thyroid Cancer pp 395-409 | Cite as

Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131I

Chapter
First Online:

Abstract

The two major areas of controversy in the management of patients with differentiated thyroid cancer are when to administer an 131I therapy and, if administered, what should be the amount of prescribed activity of 131I that is administered. Although one of the more frequent factors that is cited for the two controversies is the lack of good prospective studies, these two controversies are complicated by many other factors such as (1) the use of the same terms with different definitions, (2) the use of the same terms with different objectives (e.g., destruction of remnant tissue, reduced recurrence, or decreased disease-specific mortality), (3) the use of a term with the same definition and objectives but different end points as the measure of success for those objectives (e.g., uptake, scan, stimulated or non-stimulated thyroglobulin blood level, recurrence, and/or structural evidence of disease), (4) the end points are measured at different follow-up times (e.g., 6, 9, 12 months), and (5) variability in the extent of initial surgery and different staging systems (risk assessment tools).

Keywords

131I Remnant ablation Adjuvant treatment Differentiated thyroid cancer Metastasis Prescribed activity Empiric Dosimetry Fractionation Diuretics Redifferentiation Lithium 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Khorjekar G, Van Nostrand D, Kharazi P, Kulkarni K, Garcia C, Acio E, Atkins F. Division of Nuclear Medicine, Washington Hospital Center. Washington, D.C. Can the controversy regarding selecting the prescribed activity of 131I for first-time therapies in patient with differentiation thyroid cancer be reduced by defining the terms? An educational exhibit. J Nucl Med. 2011;52S(abstract).Google Scholar
  2. 2.
    Haugen BR, Alexander EA, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff K, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.Google Scholar
  3. 3.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, The European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.CrossRefPubMedGoogle Scholar
  4. 4.
    Perros P, Colley S, Boelaert K, Evans C, Evans RM, Gerrard GE, Gilbert JA, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold KL, Taylor J, Thakker RV, Watkinson J, Williams GR. British Thyroid Association guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81 Suppl 1:1–122.CrossRefGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Thyroid carcinoma. Follicular thyroid carcinoma. V.2.2015. www.nccn.org.
  6. 6.
    Silberstein E, Alavi A, Halon H, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53:1633–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Van Nostrand D. The benefits and risks of 131I therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:1381–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Wikipedia. http://en.wikipedia.org/wiki/Prognosis. Updated 4 Dec 2014 at 22:48. Accessed 21 Dec 2014.
  9. 9.
    Wikipedia. http://en.wikipedia.org/wiki/Objective_(goal). Updated 11 Dec 2014 at 23:58. Accessed 21 Dec 2014.
  10. 10.
    Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Wartofsky L, Sherman SI, Gopal J, et al. Therapeutic controversy: the use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 1998;83:4195–203.CrossRefPubMedGoogle Scholar
  12. 12.
    Beierwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J Nucl Med. 1984;25:1287–93.PubMedGoogle Scholar
  13. 13.
    Comtois R, Theriault C, Del Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med. 1993;34:1927–30.PubMedGoogle Scholar
  14. 14.
    DeGroot KJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Doi SAR, Woodhouse NJY. Ablation of the thyroid remnant and 131-I dose in differentiated thyroid cancer. Clin Endocrinol. 2000;52:765–73.CrossRefGoogle Scholar
  16. 16.
    Heufelder AE, Gorman CA. Radioiodine therapy in the treatment of differentiated thyroid cancer: guidelines and considerations. Endocrinologist. 1991;1:273–80.Google Scholar
  17. 17.
    Hodgson DC, Brierley JD, Tsang RW, Panzarella T. Prescribing 131-I iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol. 1998;47:325–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Hung G, Tu ST, Wu IS, et al. Comparison of the effectiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants. Jpn J Clin Oncol. 2004;34:469–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Klain M, Ricard M, Leboulleux S, et al. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med. 2002;29 Suppl 2:S479–85.CrossRefGoogle Scholar
  20. 20.
    Kuni CC, Klingensmith WC. Failure of low doses of I-131 to ablate residual thyroid tissue following surgery for thyroid cancer. Radiology 1980; 137:773–74. Leung SF, Law MWM, Ho SKW. Efficacy of low-dose iodine-131 ablation of postoperative thyroid remnants: a study of 69 cases. Br J Radiol. 1992; 65:905–9.Google Scholar
  21. 21.
    Logue JP, Tang RW, Brierley JD, et al. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol. 1994;67:1127–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. NEJM. 1983;309:937–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Mazzaferri EL. Thyroid remnant 131-I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7:265–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Meier DA, Brill DR, Becker DV, et al. Procedure guideline for therapy of thyroid disease with I-131. J Nucl Med. 2002;43:856–61.PubMedGoogle Scholar
  25. 25.
    Ramacciotti C, Pretorius HT, Line B, et al. Ablation of non-malignant thyroid remnants with low doses of radioactive iodine: concise communication. J Nucl Med. 1982;23:483–9.PubMedGoogle Scholar
  26. 26.
    Samaan NA, Schultz PN, Hickey RD, et al. The results of various modalities of treatment of well-differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714–20.PubMedGoogle Scholar
  27. 27.
    Sawka AM, Tepmongkol K, Brouwers M, et al. A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–76.CrossRefPubMedGoogle Scholar
  28. 28.
    Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988;104:1063–75.CrossRefGoogle Scholar
  29. 29.
    Sisson JC. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected. J Nucl Med. 1983;24:743–5.PubMedGoogle Scholar
  30. 30.
    Verkooijen RB, Stokkel MPM, Smit JWA, et al. Radioactive I-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med. 2004;31:499–506.CrossRefGoogle Scholar
  31. 31.
    Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayn R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. NEJM. 2012;366:1674–85.CrossRefPubMedGoogle Scholar
  32. 32.
    Bal CS, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma. Cancer. 1996;77:2574–80.CrossRefPubMedGoogle Scholar
  33. 33.
    Bal CS, Kumar A, Pant GS. Radioiodine doses of 25 to 50 mCi are equally effective for thyroid remnant ablation in patients with thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:1666–73.CrossRefPubMedGoogle Scholar
  34. 34.
    DeGroot L, Reily M. Comparison of 30- and 50-mCi of doses of iodine-131 for thyroid ablation. Ann Intern Med. 1992;96:51–3.CrossRefGoogle Scholar
  35. 35.
    Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med. 1994;35:1944–50.PubMedGoogle Scholar
  36. 36.
    Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clarke PM, Franell K, McCready R, Smellie J, Frankly JA, John R, Nutting CM, Newbodl K, Lemon C, Gerrard G. NEJM. 2012;366:1674-85.Google Scholar
  37. 37.
    Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. NEJM. 2012;366:1663–73.CrossRefPubMedGoogle Scholar
  38. 38.
    Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, Belardini V, Brianzoni E, Pacini F. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013;169:23–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim WB. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroid extension. Thyroid. 2014;24(5):820–5.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Maxon HR, Smith HS. I-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin N Am. 1990;19:685–718.Google Scholar
  41. 41.
    Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;3:253–5.CrossRefGoogle Scholar
  42. 42.
    Maxon HR. Quantitative 131I therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313–23.PubMedGoogle Scholar
  43. 43.
    Maxon HR, Englaro EE, Thomas SR, et al. 131I therapy for well differentiated thyroid cancer – a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–6.PubMedGoogle Scholar
  44. 44.
    O’Connell MEA, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol. 1993;28:16–26.CrossRefPubMedGoogle Scholar
  45. 45.
    Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, Wartofsky L. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96(10):3217–25.CrossRefPubMedGoogle Scholar
  46. 46.
    Leeper R. Controversies in the treatment of thyroid cancer: the New York Memorial Hospital approach. Thyroid Today. 1982;5:1–4.Google Scholar
  47. 47.
    Kulkarni K, Van Nostrand D, Atkins FB, Aiken MJ, Burman K, Wartofsky L. The frequency with which empiric amounts of radioiodine “over-” or “under-” treat patients with metastatic well-differentiated thyroid cancer. Thyroid. 2006;16:1019–23.CrossRefPubMedGoogle Scholar
  48. 48.
    Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587–91.PubMedGoogle Scholar
  49. 49.
    Leeper RD, Shimaoka K. Treatment of metastatic thyroid cancer. Clin Endocrinol Metab. 1980;9:383–404.CrossRefPubMedGoogle Scholar
  50. 50.
    Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.PubMedGoogle Scholar
  51. 51.
    Snyder WS, Ford MR, Warner GG, et al. “S” absorbed dose per unit cumulated activity for selected radionuclides and organs. In MIRD Pamphlet, no. 11. Reston: Society of Nuclear Medicine; 1975.Google Scholar
  52. 52.
    Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med. 2000;41:297–308.PubMedGoogle Scholar
  53. 53.
    Van Nostrand D, Atkins F, Moreau S, et al. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thyroid. 2009;10:1093–8.CrossRefGoogle Scholar
  54. 54.
    Hanscheid H, Lassmann M, Luster M, et al. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocrinol Relat Cancer. 2009;16:1283–9.CrossRefGoogle Scholar
  55. 55.
    Wikipedia. http://en.wikipedia.org/wiki/Dose_fractionation. Updated 16 Sept 2013 at 08:17. Accessed 21 Dec 2014.
  56. 56.
    Hall EJ, Giaccia AJ. Fractionated radiation and the dose-rate effect. In: Hall EJ, Giaccia AJ, editors. Radiobiology for the radiologists, 2nd edn, Philadelphia: Wolters Kluwer; 2012. p. 67–85.Google Scholar
  57. 57.
    Arad E, Flannery K, Wilson GA, O’Mara R. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nucl Med. 1990;10:676–7.CrossRefGoogle Scholar
  58. 58.
    Wang SJ, Liu TJ. Use of fractionated doses of iodine-131 for ablation of thyroid remnants. Chin Med J (Taipei). 2002;65:336–40.Google Scholar
  59. 59.
    Wu HS, Hseu HH, Lin WY, Wang SJ, Kiu YC. Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imag. 2005;32:167–73.CrossRefGoogle Scholar
  60. 60.
    Czepczynski R, Ziemnicka K, Baczyk M, Oleksa R, Ruchala M, Sowinski J. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma. Thyroid. 2005;15:1261–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Clerc J, Bienvenu-Perrard M, Pichard de Malleray C, Dagousset F, Delbot T, Dreyfuss M, Groussin L, Marlow RJ, Leger FA, Chevalie A. Outpatient thyroid remnant ablation using repeated low 131-iodine activities (740 GBq/20mCi x 2) in patients with low-risk differentiated thyroid cancer. JCEM. 2012;97:871–80.PubMedGoogle Scholar
  62. 62.
    Fregly MJ, Gennaro JF. Effect of thiazides on metacorticoid hypertension and on thyroid activity of rats. Can J Physiol Pharm. 1973;43:521–30.CrossRefGoogle Scholar
  63. 63.
    Seabold JE, Ben-Haim S, Pettit WA, et al. Diuretic enhanced I-131 clearance after ablation therapy for differentiated thyroid cancer. Radiology. 1993;187:839–42.CrossRefPubMedGoogle Scholar
  64. 64.
    Maruca J, Santner S, Miller K, Santen RJ. Prolonged iodine clearance with a depletion regimen for thyroid carcinoma: concise communication. J Nucl Med. 1984;25:1089–93.PubMedGoogle Scholar
  65. 65.
    McCarthy JS, Fregly MJ, Nechay BR. Effect of diuretics on renal iodide excretion by rats and dogs. J Pharm Exp Ther. 1967;158:294–304.Google Scholar
  66. 66.
    Fregly MJ. Effect of thiazides on the thyroid gland of rats. Toxicol Appl Pharm. 1965;8:558–66.CrossRefGoogle Scholar
  67. 67.
    Kapucu LO, Azizoglu F, Ayvaz G, Karakoc A. Effects of diuretics on iodine uptake in non-toxic goiter-comparison with low-iodine diet. Eur J Nucl Med Mol Imaging. 2003;30:L1270–2.CrossRefGoogle Scholar
  68. 68.
    Tepmongkol S. Enhancement of radioiodine uptake in hyperthyroidism with hydrochlorothiazide: a prospective randomized control study. Eur J Nucl Med Mol Imaging. 2002;29:1307–10.CrossRefPubMedGoogle Scholar
  69. 69.
    Ding H, Kuang AR, Guan CT. Randomized controlled trial of hydrochlorothiazide in augmenting the dose of 131I absorbed by thyroid remnant. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004;35:546–8.PubMedGoogle Scholar
  70. 70.
    Norfray JF, Quinn JL. Furosemide mediated elevations of thyroid uptake in the rat. Proc Soc Exp Biol Med. 1974;145:286–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Hamburger JI. Diuretic augmentation of 131-I uptake in inoperable thyroid cancer. N Eng J Med. 1969;280:1091–4.CrossRefGoogle Scholar
  72. 72.
    Matovic M, Jankovic S, Jeremic M, Tasic Z, Vlajkovic M. Unexpected effect of furosemide on radioiodine excretion in patients with differentiated thyroid carcinomas treated with iodine 131. Thyroid. 2009;19:843–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Barbaro D, Gross M, Boni G, Lapi P, Pasquini C, Orsini P, Turco A, Meucci G, Marzola MC, Berti P, Miccoli P, Marinai G, Rubello D. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging. 2010;37:242–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. NEJM. 2013;2013(368):623–32.CrossRefGoogle Scholar
  75. 75.
    Reynolds JC. Comparison of I-131 absorbed radiation doses in children and adults; a tool for estimating therapeutic I-131 doses in children. In: Robbins J, editor. Treatment of thyroid cancer in children. Springfield: US Department of Commerce Technology Administration, National Technical Information Service; 1994. p. 127–35.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Nuclear Medicine Research, MedStar Research Institute and Washington Hospital CenterGeorgetown University School of Medicine, Washington Hospital CenterWashington, DCUSA

Personalised recommendations